FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to compounds of the formula (I):
wherein r = 1, 2 or 3; s = 0; t = 0; R1 is taken among group including R11-CO and R12-SO2- wherein R11 is taken among group including (C6-C14)-aryl, (C1-C8)-alkyloxy-group wherein all given group are unsubstituted or substituted with a single or some similar or different substitutes R40; R12 means (C6-C14)-aryl wherein indicated group is unsubstituted or substituted with a single or some similar or different substituted R40; R2 means R21(R22)CH-, R23-Het-(CH2)k-, R23(R24)N-(CH2)m-D-(CH2)n- or R25(R26)N-CO-(CH2)p-D-(CH2)q- wherein D means bivalent residue -C(R31)(R32)-, bivalent (C6-C14)-arylene residue or bivalent residue obtained from aromatic group Het comprising 5 or 6 atoms in cycle among them 1 or 2 are similar or different cyclic heteroatoms taken among group including nitrogen and sulfur atoms; numbers k, m, n, p and q = 0, 1, 2; R21 and R22 that are independent of one another can be similar or different and taken among group including hydrogen atom, (C1-C12)-alkyl, (C6-C14)-aryl and so on; R23 means hydrogen atom, R27-SO2- or R28-CO-; R24, R25 and R26 mean hydrogen atom; R27 is taken among group including (C1-C8)-alkyl, (C6-C14)-aryl and so on; R28 is taken among group including R27, (C1-C8)-alkyloxy-group; R31 and R32 mean hydrogen atom; R40 is taken among group including halogen atom, hydroxy-, (C1-C8)-alkyloxy-group, (C1-C8)-alkyl, (C6-C14)-aryl and so on; R91, R92, R93 and R96 means hydrogen atom; R95 means amidino-group; R97 means R99-(C1-C8)-alkyl; R99 is taken among group including hydroxycarbonyl- and (C1-C8)-alkyloxycarbonyl-; Het means saturated, partially unsaturated or aromatic monocyclic structure comprising from 3 to 6 atoms in cycle among them 1 or 2 are similar or different heteroatoms taken among group comprising nitrogen and sulfur atoms; in all its stereoisomeric forms and also their mixtures in any ratios, and its physiologically acceptable salts. Invention proposes a method for preparing compound of the formula (I). Also, invention proposes a pharmaceutical preparation eliciting inhibitory activity with respect to factor VIIA and containing at least one compound of the formula (I) and/or its physiologically acceptable salts and pharmaceutically acceptable carrier. Invention provides preparing compounds of the formula (I) eliciting power anti-thrombosis effect and useful for treatment and prophylaxis of thrombosis-embolic diseases.
EFFECT: valuable medicinal properties of compounds and composition.
10 cl, 70 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORS OF VIIA FACTOR | 1999 |
|
RU2223967C2 |
| DERIVATIVES OF (THIO)UREA INHIBITING VIIa FACTOR, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2286337C2 |
| N-GUANIDINOALKYLAMINES, PRODUCTION, USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | 2000 |
|
RU2253651C2 |
| SUBSTITUTED DERIVATIVES OF IMIDAZOLIDINE, METHOD FOR PREPARING AND PHARMACEUTICAL PREPARATION | 1998 |
|
RU2239641C2 |
| NEW FIVE-MEMBER HETEROCYCLES, THEIR PREPARING, THEIR APPLYING AND PHARMACEUTICAL PREPARATIONS COMPRISING THEREOF | 1998 |
|
RU2240326C2 |
| HETEROARYL-SUBSTITUTED AMIDES CONTAINING SATURATED BINDING GROUP AND USE THEREOF AS PHARMACEUTICAL AGENTS | 2006 |
|
RU2412181C2 |
| NOVEL DERIVATIVES OF IMIDAZOLIDINE, THEIR PREPARING AND USING AS VLA-4 ANTAGONIST | 2002 |
|
RU2318815C2 |
| AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
| COMPOSITION FOR PREPARING METATHESIS POLYMERIZATES | 1995 |
|
RU2171815C2 |
| FIVE-MEMBERED HETEROCYCLES AS INHIBITORS OF LEUKOCYTE ADHESION AND VLA-4 ANTAGONISTS | 1997 |
|
RU2229296C2 |
